

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 2008345135 C1

(54) Title
Recombinant VWF formulations

(51) International Patent Classification(s)
B01D 61/22 (2006.01) **A61K 9/08** (2006.01)
A61K 9/00 (2006.01) **A61K 38/00** (2006.01)

(21) Application No: **2008345135** **(22) Date of Filing:** **2008.12.23**

(87) WIPO No: **WO09/086400**

(30) Priority Data

(31) Number	(32) Date	(33) Country
61/017,881	2007.12.31	US
61/017,418	2007.12.28	US

(43) Publication Date: **2009.07.09**
(44) Accepted Journal Date: **2014.02.13**
(44) Amended Journal Date: **2015.04.30**

(71) Applicant(s)
Baxter International Inc.;Baxter Healthcare SA

(72) Inventor(s)
Matthiessen, Peter;Schwarz, Hans-Peter;Turecek, Peter;Schnecker, Kurt

(74) Agent / Attorney
Wrays, Ground Floor 56 Ord Street, West Perth, WA, 6005

(56) Related Art
WO 1993/000107
US 6005077
US 5900476

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 July 2009 (09.07.2009)

(10) International Publication Number
WO 2009/086400 A3

(51) International Patent Classification:
B01D 61/22 (2006.01) *A61K 9/00* (2006.01)
A61K 9/08 (2006.01) *A61K 38/00* (2006.01)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:
PCT/US2008/088201

(22) International Filing Date:
23 December 2008 (23.12.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/017,418 28 December 2007 (28.12.2007) US
61/017,881 31 December 2007 (31.12.2007) US

(71) Applicants (for all designated States except US): **BAXTER INTERNATIONAL INC.** [US/US]; One Baxter Parkway, Deerfield, IL 60015 (US). **BAXTER HEALTHCARE SA** [CH/CH]; Hertistrasse 2, CH-8304 Wallisellen (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MATTHIESSEN, Peter** [DE/AT]; Vorgartenstrasse 129-143/1/5, A-1020 Vienna (AT). **TURECEK, Peter** [AT/AT]; Weidling, Hauptstrasse 59g, A-3400 Klosterneuburg (AT). **SCHWARZ, Hans-Peter** [AT/AT]; Poetzeleinsdorfer Strasse 50/9/2, A-1180 Vienna (AT). **SCHNECKER, Kurt** [AT/AT]; Promenadeweg 6, A-1170 Vienna (AT).

(74) Agent: **WEINSTEIN, Peter, D.**; Baxter International Inc., One Baxter Parkway, DF 2-2e, Deerfield, IL 60015 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

22 October 2009

WO 2009/086400 A3

(54) Title: RECOMBINANT VWF FORMULATIONS

(57) Abstract: The present invention provides long-term stable pharmaceutical formulations of recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.

RECOMBINANT VWF FORMULATIONS

This application claims priority of U.S. Provisional Application No. 61/017,418, filed December 28, 2007, and U.S. Provisional Application No. 61/017,881 filed December 31, 2007, each of which is incorporated by reference herein in its entirety.

FIELD OF THE INVENTION

[0001] Generally, the invention relates to formulations of recombinant VWF and methods for making a composition comprising recombinant VWF.

BACKGROUND OF THE INVENTION

[0002] Von Willebrand factor (VWF) is a glycoprotein circulating in plasma as a series of multimers ranging in size from about 500 to 20,000 kD. Multimeric forms of VWF are composed of 250 kD polypeptide subunits linked together by disulfide bonds. VWF mediates initial platelet adhesion to the sub-endothelium of the damaged vessel wall. Only the larger multimers exhibit hemostatic activity. It is assumed that endothelial cells secrete large polymeric forms of VWF and those forms of VWF which have a low molecular weight (low molecular weight VWF) arise from proteolytic cleavage. The multimers having large molecular masses are stored in the Weibel-Pallade bodies of endothelial cells and liberated upon stimulation.

[0003] VWF is synthesized by endothelial cells and megakaryocytes as prepro-VWF that consists to a large extent of repeated domains. Upon cleavage of the signal peptide, pro-VWF dimerizes through disulfide linkages at its C-terminal region. The dimers serve as protomers for multimerization, which is governed by disulfide linkages between the free end termini. The assembly to multimers is followed by the proteolytic removal of the propeptide sequence (Leyte et al., Biochem. J. 274 (1991), 257-261).

[0004] The primary translation product predicted from the cloned cDNA of VWF is a 2813-residue precursor polypeptide (prepro-VWF). The prepro-VWF consists of a 22 amino acid signal peptide and a 741 amino acid propeptide, with the mature VWF comprising 2050 amino acids (Ruggeri Z.A., and Ware, J., FASEB J., 308-316 (1993)).

[0005] Defects in VWF are causal to Von Willebrand disease (VWD), which is characterized by a more or less pronounced bleeding phenotype. VWD type 3 is the most severe form in which VWF is completely missing, and VWD type 1 relates to a quantitative loss of VWF and its phenotype can be very mild. VWD type 2 relates to qualitative defects of VWF and can be as severe as VWD type 3. VWD type 2 has many sub forms, some being associated with the loss or the decrease of high molecular weight multimers. Von Willebrand syndrome type 2a (VWS-2A) is characterized by a loss of both intermediate and large multimers. VWS-2B is characterized by a loss of highest-molecular-weight multimers. Other diseases and disorders related to VWF are known in the art.

[0006] US. Patent Nos. 6,531,577, 7,166,709, and European Patent Application No. 04380188.5, describe plasma-derived VWF formulations. However, in addition to quantity and purity issues with plasma-derived VWF, there is also a risk of blood-born pathogens (e.g., viruses and Variant Creutzfeldt-Jakob disease (vCJD).

[0007] Thus there exists a need in the art to develop a stable pharmaceutical formulation comprising recombinant VWF.

SUMMARY OF THE INVENTION

[0008] The present invention provides formulations useful for compositions comprising recombinant VWF, resulting in a highly stable pharmaceutical composition. The stable pharmaceutical composition is useful as a therapeutic agent in the treatment of individuals suffering from disorders or conditions that can benefit from the administration of recombinant VWF.

[0009] In one embodiment, the invention provides a stable liquid pharmaceutical formulation of a recombinant von Willebrand Factor (rVWF) comprising: (a) a rVWF; (b) a buffering agent; (c) one or more salts; (d) optionally a stabilizing agent; and (e) optionally a surfactant; wherein the rVWF comprises a polypeptide selected from the group consisting of: a) the amino acid sequence set out in SEQ ID NO: 3; b) a biologically active analog, fragment or variant of a); c) a polypeptide encoded by the polynucleotide set out in SEQ ID NO: 1; d) a biologically active analog, fragment or variant of c); and e) a polypeptide encoded by a polynucleotide that hybridizes to the polynucleotide set out in SEQ ID NO: 1 under moderately stringent hybridization conditions; wherein the buffer is comprised of a pH buffering agent in a range of about 0.1 mM to about 500 mM and wherein the pH is in a range of about 2.0 to about 12.0; wherein the salt is at a concentration of about 1 to 500 mM;

wherein the stabilizing agent is at a concentration of about 0.1 to 1000 mM; and wherein the surfactant is at a concentration of about 0.01 g/L to 0.5 g/L.

[009A] In one embodiment, there is provided a stable liquid pharmaceutical formulation of a recombinant von Willebrand Factor (rVWF) comprising: (a) a rVWF; (b) a buffering agent; and (c) one or more salts, wherein said rVWF in the pharmaceutical formulation causes agglutination of stabilized platelets in the presence of ristocetin, is stable for at least 26 weeks at 4°C and comprises a polypeptide that has a molecular weight of approximately 250 kDa selected from the group consisting of:

- a) the amino acid sequence set out in SEQ ID NO: 3;
- b) a biologically active analog or variant of a);
- c) a polypeptide encoded by the polynucleotide set out in SEQ ID NO: 1;
- d) a biologically active analog or variant of c); and
- e) a polypeptide encoded by a polynucleotide that hybridizes to the polynucleotide set out in SEQ ID NO: 1 under moderately stringent hybridization conditions,

wherein said buffering agent is citrate at a concentration of about 0.1 mM to about 500 mM, wherein the pH is in a range of about 3.0 to 9.0, and wherein said salt is at a concentration of about 0.5 mM to 500 mM

[0010] In another embodiment, the aforementioned formulation is provided wherein the rVWF comprises the amino acid sequence set out in SEQ ID NO: 3. In another embodiment, an aforementioned formulation is provided wherein the buffering agent is selected from the group consisting of sodium citrate, glycine, histidine, Tris and combinations of these agents. In yet another embodiment, an aforementioned formulation is provided wherein the buffering agent is citrate. In still another embodiment of the invention, the aforementioned formulation is provided wherein pH is in the range of 6.0-8.0, or 6.5-7.3. In a related embodiment, the aforementioned formulation is provided wherein the pH is 7.0. In another embodiment, an aforementioned formulation is provided wherein the buffering agent is citrate and the pH is 7.0.

[0011] In still another embodiment, an aforementioned formulation is provided wherein the salt is selected from the group consisting of calcium chloride, sodium chloride and magnesium chloride. In another embodiment, the aforementioned formulation is provided wherein

the salt is at a concentration range of 0.5 to 300 mM. In another embodiment, the aforementioned formulation is provided wherein the salt is calcium chloride at a concentration of 10 mM.

[0012] In another embodiment, an aforementioned formulation is provided wherein the rVWF comprises the amino acid sequence set out in SEQ ID NO: 3; wherein the buffering agent is citrate and the pH is 7.0; and wherein the salt is calcium chloride at a concentration of 10 mM. In still another embodiment, an aforementioned formulation is provided wherein the rVWF comprises the amino acid sequence set out in SEQ ID NO: 3; wherein the buffering agent is sodium citrate and the pH is 7.0; and wherein the salt is calcium chloride at a concentration of 10 mM and NaCl at a concentration of 100 mM.

[0013] Other formulations are also contemplated by the instant invention. For example, in one embodiment, an aforementioned formulation is provided wherein the one or more buffering agents is histidine and Tris at a concentration of 3.3 mM each. In another embodiment, the aforementioned formulation is provided wherein the pH is 7.0. In yet another embodiment, an aforementioned formulation is provided wherein the first salt is sodium chloride at a concentration of 30 mM and the second salt is calcium chloride at a concentration of 0.56 mM.

[0014] In still another embodiment of the invention, an aforementioned formulation is provided wherein the stabilizing agent is selected from the group consisting of mannitol, lactose, sorbitol, xylitol, sucrose, trehalose, mannose, maltose, lactose, glucose, raffinose, cellobiose,

gentiobiose, isomaltose, arabinose, glucosamine, fructose and combinations of these stabilizing agents. In another embodiment, the aforementioned formulation is provided wherein the stabilizing agents are trehalose at a concentration of 7.8 mM and mannitol at a concentration of 58.6 mM.

[0015] In another embodiment, an aforementioned formulation is provided wherein the surfactant is selected from the group consisting of digitonin, Triton X-100, Triton X-114, TWEEN-20, TWEEN-80 and combinations of these surfactants. In another embodiment, the aforementioned formulation is provided wherein the surfactant is TWEEN-80 at 0.03 g/L.

[0016] In one embodiment of the invention, an aforementioned formulation is provided wherein the rVWF comprises amino acid sequence set out in SEQ ID NO: 3; wherein the buffering agents are histidine at a concentration of 3.3 mM and Tris at a concentration of 3.3 mM at pH 7.0; wherein the first salt is sodium chloride at a concentration of 30 mM and the second salt is calcium chloride at a concentration of 0.56 mM; wherein the stabilizing agents are trehalose at a concentration of 7.8 mM mannitol at a concentration of 58.6 mM; and wherein the surfactant is TWEEN-80 at 0.03 g/L.

[0016a] Definitions of the specific embodiments of the invention as claimed herein follow.

[0016b] According to a first embodiment of the invention, there is provided a stable liquid pharmaceutical formulation of a recombinant von Willebrand Factor (rVWF) comprising:

(a) a rVWF; (b) a buffering agent; and (c) one or more salts,

wherein said rVWF in the pharmaceutical formulation is stable for at least 26 weeks at 4°C and comprises a polypeptide that has a molecular weight of approximately 250 kDa selected from the group consisting of:

- a) the amino acid sequence set out in SEQ ID NO: 3;
- b) a biologically active analog or variant of a);
- c) a polypeptide encoded by the polynucleotide set out in SEQ ID NO: 1;
- d) a biologically active analog or variant of c); and
- e) a polypeptide encoded by a polynucleotide that hybridizes to the

polynucleotide set out in SEQ ID NO: 1 under moderately stringent hybridization conditions,

wherein said buffering agent is citrate at a concentration of about 0.1 mM to about 500 mM,

wherein the pH is in a range of about 2.0 to 12.0, and

wherein said salt is at a concentration of about 0.5 mM to 500 mM.

[0016c] According to a second embodiment of the invention, there is provided a stable liquid pharmaceutical formulation of a recombinant von Willebrand Factor (rVWF) comprising: (a) a rVWF; (b) a buffering agent; and (c) one or more salts,

wherein said rVWF in the pharmaceutical formulation is stable for at least 26 weeks at 4°C and comprises a polypeptide that has a molecular weight of approximately 250 kDa selected from the group consisting of:

- a) the amino acid sequence set out in SEQ ID NO: 3;
- b) a biologically active analog or variant of a);
- c) a polypeptide encoded by the polynucleotide set out in SEQ ID NO: 1;
- d) a biologically active analog or variant of c); and
- e) a polypeptide encoded by a polynucleotide that hybridizes to the

polynucleotide set out in SEQ ID NO: 1 under moderately stringent hybridization conditions,

wherein the buffering agent is citrate at a concentration of about 15 mM,

wherein the pH is in a range of about 2.0 to 12.0, and

wherein a first salt is sodium chloride at a concentration of about 100 mM

and a second salt is sodium chloride at a concentration of about 10 mM.

[0016d] Any reference to publications cited in this specification is not an admission that the disclosures constitute common general knowledge in Australia.

BRIEF DESCRIPTION OF THE FIGURES

[0017] **Figure 1** shows that rVWF is not stable in Advate buffer after 26 weeks, due to the presence of glutathione.

[0018] **Figure 2** shows that rVWF is stable in Advate 1:3 buffer for up to 12 weeks at 4°C.

[0019] **Figure 3** shows that the stability of a citrate-based formulation is better than Advate 1:3 buffer formulation containing 0.1 M glutathione.

[0020] **Figure 4** shows that rVWF concentration is stable over 26 weeks in Advate buffer.

[0021] **Figure 5** shows that rVWF concentration is stable over time in Advate 1:3 buffer.

[0022] **Figure 6** shows that rVWF concentration is stable over time in citrate-based buffer.

[0023] **Figure 7** shows that most excipients increase the unfolding temperature of rVWF by about 1 or 2°C.

[0024] **Figure 8** shows that 10 mM CaCl₂ increases unfolding temperature of rVWF by about 8°C to about 67°C.

[Text continues on page 5.]

[0025] **Figure 9** shows that the effect of CaCl₂ is similar at pH 7.3 and pH 6.5.

DETAILED DESCRIPTION OF THE INVENTION

Definition of terms

[0026] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton, et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY (2d ed. 1994); THE CAMBRIDGE DICTIONARY OF SCIENCE AND TECHNOLOGY (Walker ed., 1988); THE GLOSSARY OF GENETICS, 5TH ED., R. Rieger, et al. (eds.), Springer Verlag (1991); and Hale and Marham, THE HARPER COLLINS DICTIONARY OF BIOLOGY (1991).

[0027] Each publication, patent application, patent, and other reference cited herein is incorporated by reference in its entirety to the extent that it is not inconsistent with the present disclosure.

[0028] It is noted here that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise.

[0029] As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

[0030] The term "comprising," with respect to a peptide compound, means that a compound may include additional amino acids at either or both amino and carboxy termini of the given sequence. Of course, these additional amino acids should not significantly interfere with the activity of the compound. With respect to a composition of the instant invention, the term "comprising" means that a composition may include additional components. These additional components should not significantly interfere with the activity of the composition.

[0031] The term "pharmacologically active" means that a substance so described is determined to have activity that affects a medical parameter (e.g., but not limited to blood pressure, blood cell count, cholesterol level) or disease state (e.g., but not limited to cancer, autoimmune disorders).

[0032] As used herein the terms "express," "expressing" and "expression" mean allowing or causing the information in a gene or DNA sequence to become manifest, for example, producing a

protein by activating the cellular functions involved in transcription and translation of a corresponding gene or DNA sequence. A DNA sequence is expressed in or by a cell to form an "expression product" such as a protein. The expression product itself, e.g. the resulting protein, may also be said to be "expressed." An expression product can be characterized as intracellular, extracellular or secreted. The term "intracellular" means inside a cell. The term "extracellular" means outside a cell, such as a transmembrane protein. A substance is "secreted" by a cell if it appears in significant measure outside the cell, from somewhere on or inside the cell.

[0033] As used herein a "polypeptide" refers to a polymer composed of amino acid residues, structural variants, related naturally-occurring structural variants, and synthetic non-naturally occurring analogs thereof linked via peptide bonds. Synthetic polypeptides can be prepared, for example, using an automated polypeptide synthesizer. The term "protein" typically refers to large polypeptides. The term "peptide" typically refers to short polypeptides.

[0034] As used herein a "fragment" of a polypeptide is meant to refer to any portion of a polypeptide or protein smaller than the full-length polypeptide or protein expression product.

[0035] As used herein an "analog" refers to any of two or more polypeptides substantially similar in structure and having the same biological activity, but can have varying degrees of activity, to either the entire molecule, or to a fragment thereof. Analogs differ in the composition of their amino acid sequences based on one or more mutations involving substitution of one or more amino acids for other amino acids. Substitutions can be conservative or non-conservative based on the physico-chemical or functional relatedness of the amino acid that is being replaced and the amino acid replacing it.

[0036] As used herein a "variant" refers to a polypeptide, protein or analog thereof that is modified to comprise additional chemical moieties not normally a part of the molecule. Such moieties may modulate the molecule's solubility, absorption, biological half-life, etc. The moieties may alternatively decrease the toxicity of the molecule and eliminate or attenuate any undesirable side effect of the molecule, etc. Moieties capable of mediating such effects are disclosed in Remington's Pharmaceutical Sciences (1980). Procedure for coupling such moieties to a molecule are well known in the art. For example, the variant may be a blood clotting factor having a chemical modification which confers a longer half-life in vivo to the protein. In various aspects, polypeptides are modified by glycosylation, pegylation, and/or polysialylation.

[0037] Recombinant VWF

[0038] The polynucleotide and amino acid sequences of prepro-VWF are set out in SEQ ID NO:1 and SEQ ID NO:2, respectively, and are available at GenBank Accession Nos. NM_000552 and NP_000543, respectively. The amino acid sequence corresponding to the mature VWF protein is set out in SEQ ID NO: 3 (corresponding to amino acids 764-2813 of the full length prepro-VWF amino acid sequence).

[0039] One form of useful rVWF has at least the property of in vivo-stabilizing, e.g. binding, of at least one Factor VIII (FVIII) molecule and having optionally a glycosylation pattern which is pharmacologically acceptable. Specific examples thereof include VWF without A2 domain thus resistant to proteolysis (Lankhof et al., Thromb. Haemost. 77: 1008-1013, 1997), and the VWF fragment from Val 449 to Asn 730 including the glycoprotein Ib-binding domain and binding sites for collagen and heparin (Pietu et al., Biochem. Biophys. Res. Commun. 164: 1339-1347, 1989). The determination of the ability of a VWF to stabilize at least one FVIII molecule can be carried out in VWF-deficient mammals according to methods known in the state in the art.

[0040] The rVWF of the present invention may be produced by any method known in the art. One specific example is disclosed in WO86/06096 published on Oct. 23, 1986 and U.S. Patent Application No. 07/559,509, filed on Jul. 23, 1990, which is incorporated herein by reference with respect to the methods of producing recombinant VWF. Thus, methods are known in the art for (i) the production of recombinant DNA by genetic engineering, e.g. via reverse transcription of RNA and/or amplification of DNA, (ii) introducing recombinant DNA into prokaryotic or eukaryotic cells by transfection, e.g. via electroporation or microinjection, (iii) cultivating said transformed cells, e.g. in a continuous or batchwise manner, (iv) expressing VWF, e.g. constitutively or upon induction, and (v) isolating said VWF, e.g. from the culture medium or by harvesting the transformed cells, in order to (vi) obtain purified rVWF, e.g. via anion exchange chromatography or affinity chromatography. A recombinant VWF may be made in transformed host cells using recombinant DNA techniques well known in the art. For instance, sequences coding for the polypeptide could be excised from DNA using suitable restriction enzymes.

[0041] Alternatively, the DNA molecule could be synthesized using chemical synthesis techniques, such as the phosphoramidate method. Also, a combination of these techniques could be used.

[0042] The invention also provides vectors encoding polypeptides of the invention in an appropriate host. The vector comprises the polynucleotide that encodes the polypeptide operatively linked to appropriate expression control sequences. Methods of effecting this operative linking,

either before or after the polynucleotide is inserted into the vector, are well known. Expression control sequences include promoters, activators, enhancers, operators, ribosomal binding sites, start signals, stop signals, cap signals, polyadenylation signals, and other signals involved with the control of transcription or translation. The resulting vector having the polynucleotide therein is used to transform an appropriate host. This transformation may be performed using methods well known in the art.

[0043] Any of a large number of available and well-known host cells may be used in the practice of this invention. The selection of a particular host is dependent upon a number of factors recognized by the art, including, for example, compatibility with the chosen expression vector, toxicity of the peptides encoded by the DNA molecule, rate of transformation, ease of recovery of the peptides, expression characteristics, bio-safety and costs. A balance of these factors must be struck with the understanding that not all host cells are equally effective for the expression of a particular DNA sequence. Within these general guidelines, useful microbial host cells include bacteria, yeast and other fungi, insects, plants, mammalian (including human) cells in culture, or other hosts known in the art.

[0044] Next, the transformed host is cultured and purified. Host cells may be cultured under conventional fermentation conditions so that the desired compounds are expressed. Such fermentation conditions are well known in the art. Finally, the polypeptides are purified from culture by methods well known in the art.

[0045] Depending on the host cell utilized to express a compound of the invention, carbohydrate (oligosaccharide) groups may conveniently be attached to sites that are known to be glycosylation sites in proteins. Generally, O-linked oligosaccharides are attached to serine (Ser) or threonine (Thr) residues while N-linked oligosaccharides are attached to asparagine (Asn) residues when they are part of the sequence Asn-X-Ser/Thr, where X can be any amino acid except proline. X is preferably one of the 19 naturally occurring amino acids not counting proline. The structures of N-linked and O-linked oligosaccharides and the sugar residues found in each type are different. One type of sugar that is commonly found on both is N-acetylneurameric acid (referred to as sialic acid). Sialic acid is usually the terminal residue of both N-linked and O-linked oligosaccharides and, by virtue of its negative charge, may confer acidic properties to the glycosylated compound. Such site(s) may be incorporated in the linker of the compounds of this invention and are preferably glycosylated by a cell during recombinant production of the polypeptide compounds (e.g., in mammalian cells such as CHO, BHK, COS). However, such sites may further be glycosylated by synthetic or semi-synthetic procedures known in the art.

[0046] Alternatively, the compounds may be made by synthetic methods. For example, solid phase synthesis techniques may be used. Suitable techniques are well known in the art, and include those described in Merrifield (1973), *Chem. Polypeptides*, pp. 335-61 (Katsoyannis and Panayotis eds.); Merrifield (1963), *J. Am. Chem. Soc.* 85: 2149; Davis et al. (1985), *Biochem. Intl.* 10: 394-414; Stewart and Young (1969), *Solid Phase Peptide Synthesis*; U.S. Pat. No. 3,941,763; Finn et al. (1976), *The Proteins* (3rd ed.) 2: 105-253; and Erickson et al. (1976), *The Proteins* (3rd ed.) 2: 257-527. Solid phase synthesis is the preferred technique of making individual peptides since it is the most cost-effective method of making small peptides.

[0047] Fragments, variants and analogs of VWF

[0048] Methods for preparing polypeptide fragments, variants or analogs are well-known in the art.

[0049] Fragments of a polypeptide are prepared using, without limitation, enzymatic cleavage (e.g., trypsin, chymotrypsin) and also using recombinant means to generate a polypeptide fragments having a specific amino acid sequence. Polypeptide fragments may be generated comprising a region of the protein having a particular activity, such as a multimerization domain or any other identifiable VWF domain known in the art.

[0050] Methods of making polypeptide analogs are also well-known. Amino acid sequence analogs of a polypeptide can be substitutional, insertional, addition or deletion analogs. Deletion analogs, including fragments of a polypeptide, lack one or more residues of the native protein which are not essential for function or immunogenic activity. Insertional analogs involve the addition of, e.g., amino acid(s) at a non-terminal point in the polypeptide. This analog may include insertion of an immunoreactive epitope or simply a single residue. Addition analogs, including fragments of a polypeptide, include the addition of one or more amino acids at either of both termini of a protein and include, for example, fusion proteins.

[0051] Substitutional analogs typically exchange one amino acid of the wild-type for another at one or more sites within the protein, and may be designed to modulate one or more properties of the polypeptide without the loss of other functions or properties. In one aspect, substitutions are conservative substitutions. By "conservative amino acid substitution" is meant substitution of an amino acid with an amino acid having a side chain of a similar chemical character. Similar amino acids for making conservative substitutions include those having an acidic side chain (glutamic acid, aspartic acid); a basic side chain (arginine, lysine, histidine); a polar amide side chain (glutamine, asparagine); a hydrophobic, aliphatic side chain (leucine, isoleucine, valine, alanine, glycine); an

aromatic side chain (phenylalanine, tryptophan, tyrosine); a small side chain (glycine, alanine, serine, threonine, methionine); or an aliphatic hydroxyl side chain (serine, threonine).

[0052] Analogs may be substantially homologous or substantially identical to the recombinant VWF from which they are derived. Preferred analogs are those which retain at least some of the biological activity of the wild-type polypeptide, *e.g.* blood clotting activity.

[0053] Polypeptide variants contemplated include polypeptides chemically modified by such techniques as ubiquitination, glycosylation, including polysialation, conjugation to therapeutic or diagnostic agents, labeling, covalent polymer attachment such as pegylation (derivatization with polyethylene glycol), introduction of non-hydrolyzable bonds, and insertion or substitution by chemical synthesis of amino acids such as ornithine, which do not normally occur in human proteins. Variants retain the same or essentially the same binding properties of non-modified molecules of the invention. Such chemical modification may include direct or indirect (*e.g.*, via a linker) attachment of an agent to the VWF polypeptide. In the case of indirect attachment, it is contemplated that the linker may be hydrolyzable or non-hydrolyzable.

[0054] Preparing pegylated polypeptide analogs will generally comprise the steps of (a) reacting the polypeptide with polyethylene glycol (such as a reactive ester or aldehyde derivative of PEG) under conditions whereby the binding construct polypeptide becomes attached to one or more PEG groups, and (b) obtaining the reaction product(s). In general, the optimal reaction conditions for the acylation reactions will be determined based on known parameters and the desired result. For example, the larger the ratio of PEG: protein, the greater the percentage of poly-pegylated product. In some embodiments, the binding construct will have a single PEG moiety at the N-terminus. Polyethylene glycol (PEG) may be attached to the blood clotting factor to provide a longer half-life *in vivo*. The PEG group may be of any convenient molecular weight and may be linear or branched. The average molecular weight of the PEG ranges from about 2 kiloDalton ("kD") to about 100 kDa, from about 5 kDa to about 50 kDa, or from about 5 kDa to about 10 kDa. The PEG groups are attached to the blood clotting factor via acylation or reductive alkylation through a natural or engineered reactive group on the PEG moiety (*e.g.*, an aldehyde, amino, thiol, or ester group) to a reactive group on the blood clotting factor (*e.g.*, an aldehyde, amino, or ester group) or by any other technique known in the art.

[0055] Methods for preparing polysialylated polypeptide are described in United States Patent Publication 20060160948, Fernandes et Gregoriadis; *Biochim. Biophys. Acta* 1341: 26-34, 1997, and Saenko et al., *Haemophilia* 12:42-51, 2006. Briefly, a solution of colominic acid

containing 0.1 M NaIO₄ is stirred in the dark at room temperature to oxidize the CA. The activated CA solution is dialyzed against, e.g., 0.05 M sodium phosphate buffer, pH 7.2 in the dark and this solution was added to a rVWF solution and incubated for 18 h at room temperature in the dark under gentle shaking. Free reagents can then be separated from the rVWF-polysialic acid conjugate by ultrafiltration/diafiltration. Conjugation of rVWF with polysialic acid may also be achieved using glutaraldehyde as cross-linking reagent (Migneault et al., Biotechniques 37: 790-796, 2004).

[0056] It is further contemplated that a polypeptide of the invention may be a fusion protein with a second agent which is a polypeptide. In one embodiment, the second agent which is a polypeptide, without limitation, is an enzyme, a growth factor, an antibody, a cytokine, a chemokine, a cell-surface receptor, the extracellular domain of a cell surface receptor, a cell adhesion molecule, or fragment or active domain of a protein described above. In a related embodiment, the second agent is a blood clotting factor such as Factor VIII, Factor VII, Factor IX. The fusion protein contemplated is made by chemical or recombinant techniques well-known in the art.

[0057] It is also contemplated that prepro-VWF and pro-VWF polypeptides may provide a therapeutic benefit in the formulations of the present invention. For example, US Patent No. 7,005,502 describes a pharmaceutical preparation comprising substantial amounts of pro-VWF that induces thrombin generation *in vitro*. In addition to recombinant, biologically active fragments, variants, or analogs of the naturally-occurring mature VWF, the present invention contemplates the use of recombinant biologically active fragments, variants, or analogs of the prepro-VWF (set out in SEQ ID NO:2) or pro-VWF polypeptides (amino acid residues 23 to 764 of SEQ ID NO: 2) in the formulations described herein.

[0058] Polynucleotides encoding fragments, variants and analogs may be readily generated by a worker of skill to encode biologically active fragments, variants, or analogs of the naturally-occurring molecule that possess the same or similar biological activity to the naturally-occurring molecule. These polynucleotides can be prepared using PCR techniques, digestion/ligation of DNA encoding molecule, and the like. Thus, one of skill in the art will be able to generate single base changes in the DNA strand to result in an altered codon and a missense mutation, using any method known in the art, including, but not limited to site-specific mutagenesis. As used herein, the phrase "moderately stringent hybridization conditions" means, for example, hybridization at 42°C in 50% formamide and washing at 60°C in 0.1 x SSC, 0.1% SDS. It is understood by those of skill in the art that variation in these conditions occurs based on the length and GC nucleotide base content of the sequences to be hybridized. Formulas standard in the art are appropriate for determining exact

hybridization conditions. See Sambrook et al., 9.47-9.51 in Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989).

[0059] Formulations and excipients in general

[0060] Excipients are additives that are included in a formulation because they either impart or enhance the stability and delivery of a drug product. Regardless of the reason for their inclusion, excipients are an integral component of a drug product and therefore need to be safe and well tolerated by patients. For protein drugs, the choice of excipients is particularly important because they can affect both efficacy and immunogenicity of the drug. Hence, protein formulations need to be developed with appropriate selection of excipients that afford suitable stability, safety, and marketability.

[0061] The principal challenge in developing formulations for therapeutic proteins is stabilizing the product against the stresses of manufacturing, shipping and storage. The role of formulation excipients is to provide stabilization against these stresses. Excipients may also be employed to reduce viscosity of high concentration protein formulations in order to enable their delivery and enhance patient convenience. In general, excipients can be classified on the basis of the mechanisms by which they stabilize proteins against various chemical and physical stresses. Some excipients are used to alleviate the effects of a specific stress or to regulate a particular susceptibility of a specific protein. Other excipients have more general effects on the physical and covalent stabilities of proteins. The excipients described herein are organized either by their chemical type or their functional role in formulations. Brief descriptions of the modes of stabilization are provided when discussing each excipient type.

[0062] Given the teachings and guidance provided herein, those skilled in the art will know what amount or range of excipient can be included in any particular formulation to achieve a biopharmaceutical formulation of the invention that promotes retention in stability of the biopharmaceutical (e.g., a polypeptide). For example, the amount and type of a salt to be included in a biopharmaceutical formulation of the invention can be selected based on the desired osmolality (i.e., isotonic, hypotonic or hypertonic) of the final solution as well as the amounts and osmolality of other components to be included in the formulation. Similarly, by exemplification with reference to the type of polyol or sugar included in a formulation, the amount of such an excipient will depend on its osmolality.

[0063] By way of example, inclusion of about 5% sorbitol can achieve isotonicity while about 9% of a sucrose excipient is needed to achieve isotonicity. Selection of the amount or range of

concentrations of one or more excipients that can be included within a biopharmaceutical formulation of the invention has been exemplified above by reference to salts, polyols and sugars. However, those skilled in the art will understand that the considerations described herein and further exemplified by reference to specific excipients are equally applicable to all types and combinations of excipients including, for example, salts, amino acids, other tonicity agents, surfactants, stabilizers, bulking agents, cryoprotectants, lyoprotectants, anti-oxidants, metal ions, chelating agents and/or preservatives.

[0064] Further, where a particular excipient is reported in molar concentration, those skilled in the art will recognize that the equivalent percent (%) w/v (e.g., (grams of substance in a solution sample/mL of solution) X 100%) of solution is also contemplated.

[0065] Of course, a person having ordinary skill in the art would recognize that the concentrations of the excipients described herein share an interdependency within a particular formulation. By way of example, the concentration of a bulking agent may be lowered where, e.g., there is a high polypeptide concentration or where, e.g., there is a high stabilizing agent concentration. In addition, a person having ordinary skill in the art would recognize that, in order to maintain the isotonicity of a particular formulation in which there is no bulking agent, the concentration of a stabilizing agent would be adjusted accordingly (i.e., a "tonicifying" amount of stabilizer would be used). Common excipients are known in the art and can be found in Powell et al., Compendium of Excipients for Parenteral Formulations (1998), PDA J. Pharm. Sci. Technology, 52:238-311.

[0066] Buffers and buffering agents

[0067] The stability of a pharmacologically active polypeptide formulation is usually observed to be maximal in a narrow pH range. This pH range of optimal stability needs to be identified early during pre-formulation studies. Several approaches, such as accelerated stability studies and calorimetric screening studies, have been demonstrated to be useful in this endeavor (Remmele R.L. Jr., et al., *Biochemistry*, 38(16): 5241-7 (1999)). Once a formulation is finalized, the drug product must be manufactured and maintained throughout its shelf-life. Hence, buffering agents are almost always employed to control pH in the formulation.

[0068] Organic acids, phosphates and Tris have been employed routinely as buffers in protein formulations. The buffer capacity of the buffering species is maximal at a pH equal to the pKa and decreases as pH increases or decreases away from this value. Ninety percent of the

buffering capacity exists within one pH unit of its pKa. Buffer capacity also increases proportionally with increasing buffer concentration.

[0069] Several factors need to be considered when choosing a buffer. First and foremost, the buffer species and its concentration need to be defined based on its pKa and the desired formulation pH. Equally important is to ensure that the buffer is compatible with the polypeptide and other formulation excipients, and does not catalyze any degradation reactions. A third important aspect to be considered is the sensation of stinging and irritation the buffer may induce upon administration. For example, citrate is known to cause stinging upon injection (Laursen T, et al., *Basic Clin Pharmacol Toxicol.*, 98(2): 218-21 (2006)). The potential for stinging and irritation is greater for drugs that are administered via the subcutaneous (SC) or intramuscular (IM) routes, where the drug solution remains at the site for a relatively longer period of time than when administered by the IV route where the formulation gets diluted rapidly into the blood upon administration. For formulations that are administered by direct IV infusion, the total amount of buffer (and any other formulation component) needs to be monitored. One has to be particularly careful about potassium ions administered in the form of the potassium phosphate buffer, which can induce cardiovascular effects in a patient (Hollander-Rodriguez JC, et al., *Am. Fam. Physician.*, 73(2): 283-90 (2006)).

[0070] The buffer system present in the compositions is selected to be physiologically compatible and to maintain a desired pH of the pharmaceutical formulation. In one embodiment, the pH of the solution is between pH 2.0 and pH 12.0. For example, the pH of the solution may be 2.0, 2.3, 2.5, 2.7, 3.0, 3.3, 3.5, 3.7, 4.0, 4.3, 4.5, 4.7, 5.0, 5.3, 5.5, 5.7, 6.0, 6.3, 6.5, 6.7, 7.0, 7.3, 7.5, 7.7, 8.0, 8.3, 8.5, 8.7, 9.0, 9.3, 9.5, 9.7, 10.0, 10.3, 10.5, 10.7, 11.0, 11.3, 11.5, 11.7, or 12.0.

[0071] The pH buffering compound may be present in any amount suitable to maintain the pH of the formulation at a predetermined level. In one embodiment, the pH buffering concentration is between 0.1 mM and 500 mM (1 M). For example, it is contemplated that the pH buffering agent is at least 0.1, 0.5, 0.7, 0.8 0.9, 1.0, 1.2, 1.5, 1.7, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 500 mM.

[0072] Exemplary pH buffering agents used to buffer the formulation as set out herein include, but are not limited to glycine, histidine, glutamate, succinate, phosphate, acetate, citrate, Tris and amino acids or mixtures of amino acids, including, but not limited to aspartate, histidine, and glycine..

[0073] Salts

[0074] Salts are often added to increase the ionic strength of the formulation, which can be important for protein solubility, physical stability, and isotonicity. Salts can affect the physical stability of proteins in a variety of ways. Ions can stabilize the native state of proteins by binding to charged residues on the protein's surface. Alternatively, salts can stabilize the denatured state by binding to peptide groups along the protein backbone (-CONH-). Salts can also stabilize the protein native conformation by shielding repulsive electrostatic interactions between residues within a protein molecule. Salts in protein formulations can also shield attractive electrostatic interactions between protein molecules that can lead to protein aggregation and insolubility. In formulations provided, the salt concentration is between 0.1, 1, 10, 20, 30, 40, 50, 80, 100, 120, 150, 200, 300, and 500 mM.

[0075] Stabilizers and bulking agents

[0076] In the present pharmaceutical formulations, a stabilizer (or a combination of stabilizers) may be added to prevent or reduce storage-induced aggregation and chemical degradation. A hazy or turbid solution upon reconstitution indicates that the protein has precipitated or at least aggregated. The term "stabilizer" means an excipient capable of preventing aggregation or other physical degradation, as well as chemical degradation (for example, autolysis, deamidation, oxidation, etc.) in an aqueous state. Stabilizers that are conventionally employed in pharmaceutical compositions include, but are not limited to, sucrose, trehalose, mannose, maltose, lactose, glucose, raffinose, cellobiose, gentiobiose, isomaltose, arabinose, glucosamine, fructose, mannitol, sorbitol, glycine, arginine HCL, poly-hydroxy compounds, including polysaccharides such as dextran, starch, hydroxyethyl starch, cyclodextrins, N-methyl pyrrolidene, cellulose and hyaluronic acid, sodium chloride, [Carpenter et al., Develop. Biol. Standard 74:225, (1991)]. In the present formulations, the stabilizer is incorporated in a concentration of about 0.1, 0.5, 0.7, 0.8 0.9, 1.0, 1.2, 1.5, 1.7, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 500, 700, 900, or 1000 mM.

[0077] If desired, the formulations also include appropriate amounts of bulking and osmolarity regulating agents. Bulking agents include, for example, mannitol, glycine, sucrose, polymers such as dextran, polyvinylpyrrolidone, carboxymethylcellulose, lactose, sorbitol, trehalose, or xylitol. In one embodiment, the bulking agent is mannitol. The bulking agent is incorporated in a concentration of about 0.1, 0.5, 0.7, 0.8 0.9, 1.0, 1.2, 1.5, 1.7, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 500, 700, 900, or 1000 mM.

[0078] Surfactants

[0079] Protein molecules have a high propensity to interact with surfaces making them susceptible to adsorption and denaturation at air-liquid, vial-liquid, and liquid-liquid (silicone oil) interfaces. This degradation pathway has been observed to be inversely dependent on protein concentration and results in either the formation of soluble and insoluble protein aggregates or the loss of protein from solution via adsorption to surfaces. In addition to container surface adsorption, surface-induced degradation is exacerbated with physical agitation, as would be experienced during shipping and handling of the product.

[0080] Surfactants are commonly used in protein formulations to prevent surface-induced degradation. Surfactants are amphipathic molecules with the capability of out-competing proteins for interfacial positions. Hydrophobic portions of the surfactant molecules occupy interfacial positions (e.g., air/liquid), while hydrophilic portions of the molecules remain oriented towards the bulk solvent. At sufficient concentrations (typically around the detergent's critical micellar concentration), a surface layer of surfactant molecules serve to prevent protein molecules from adsorbing at the interface. Thereby, surface-induced degradation is minimized. The most commonly used surfactants are fatty acid esters of sorbitan polyethoxylates, i.e. polysorbate 20 and polysorbate 80. The two differ only in the length of the aliphatic chain that imparts hydrophobic character to the molecules, C-12 and C-18, respectively. Accordingly, polysorbate-80 is more surface-active and has a lower critical micellar concentration than polysorbate-20.

[0081] Detergents can also affect the thermodynamic conformational stability of proteins. Here again, the effects of a given detergent excipient will be protein specific. For example, polysorbates have been shown to reduce the stability of some proteins and increase the stability of others. Detergent destabilization of proteins can be rationalized in terms of the hydrophobic tails of the detergent molecules that can engage in specific binding with partially or wholly unfolded protein states. These types of interactions could cause a shift in the conformational equilibrium towards the more expanded protein states (i.e. increasing the exposure of hydrophobic portions of the protein molecule in complement to binding polysorbate). Alternatively, if the protein native state exhibits some hydrophobic surfaces, detergent binding to the native state may stabilize that conformation.

[0082] Another aspect of polysorbates is that they are inherently susceptible to oxidative degradation. Often, as raw materials, they contain sufficient quantities of peroxides to cause oxidation of protein residue side-chains, especially methionine. The potential for oxidative damage arising from the addition of stabilizer emphasizes the point that the lowest effective concentrations of excipients should be used in formulations. For surfactants, the effective concentration for a given protein will depend on the mechanism of stabilization. It has been postulated that if the mechanism

of surfactant stabilization is related to preventing surface-denaturation the effective concentration will be around the detergent's critical micellar concentration. Conversely, if the mechanism of stabilization is associated with specific protein-detergent interactions, the effective surfactant concentration will be related to the protein concentration and the stoichiometry of the interaction (Randolph T.W., et al., *Pharm Biotechnol.*, 13:159-75 (2002)).

[0083] Surfactants may also be added in appropriate amounts to prevent surface related aggregation phenomenon during freezing and drying [Chang, B, *J. Pharm. Sci.* 85:1325, (1996)]. Exemplary surfactants include anionic, cationic, nonionic, zwitterionic, and amphoteric surfactants including surfactants derived from naturally-occurring amino acids. Anionic surfactants include, but are not limited to, sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate, chenodeoxycholic acid, N-lauroylsarcosine sodium salt, lithium dodecyl sulfate, 1-octanesulfonic acid sodium salt, sodium cholate hydrate, sodium deoxycholate, and glycodeoxycholic acid sodium salt. Cationic surfactants include, but are not limited to, benzalkonium chloride or benzethonium chloride, cetylpyridinium chloride monohydrate, and hexadecyltrimethylammonium bromide. Zwitterionic surfactants include, but are not limited to, CHAPS, CHAPSO, SB3-10, and SB3-12. Non-ionic surfactants include, but are not limited to, digitonin, Triton X-100, Triton X-114, TWEEN-20, and TWEEN-80. Surfactants also include, but are not limited to lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 40, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, soy lecithin and other phospholipids such as dioleyl phosphatidyl choline (DOPC), dimyristoylphosphatidyl glycerol (DMPG), dimyristoylphosphatidyl choline (DMPC), and (dioleyl phosphatidyl glycerol) DOPG; sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. Compositions comprising these surfactants, either individually or as a mixture in different ratios, are therefore further provided. In the present formulations, the surfactant is incorporated in a concentration of about 0.01 to about 0.5 g/L.

[0084] Other common excipient components

[0085] Amino acids

[0086] Amino acids have found versatile use in protein formulations as buffers, bulking agents, stabilizers and antioxidants. Histidine and glutamic acid are employed to buffer protein formulations in the pH range of 5.5 – 6.5 and 4.0 – 5.5 respectively. The imidazole group of histidine has a pKa = 6.0 and the carboxyl group of glutamic acid side chain has a pKa of 4.3 which makes these amino acids suitable for buffering in their respective pH ranges. Glutamic acid is particularly useful in such cases (e.g., Stemgen®). Histidine is commonly found in marketed protein

formulations (e.g., Xolair®, Herceptin®, Recombinate®), and this amino acid provides an alternative to citrate, a buffer known to sting upon injection. Interestingly, histidine has also been reported to have a stabilizing effect, as observed in formulations with ABX-IL8 (an IgG2 antibody), with respect to aggregation when used at high concentrations in both liquid and lyophilized presentations (Chen B, et al., *Pharm Res.*, 20(12): 1952-60 (2003)). Histidine (up to 60 mM) was also observed to reduce the viscosity of a high concentration formulation of this antibody. However, in the same study, the authors observed increased aggregation and discoloration in histidine containing formulations during freeze-thaw studies of the antibody in stainless steel containers. The authors attributed this to an effect of iron ions leached from corrosion of steel containers. Another note of caution with histidine is that it undergoes photo-oxidation in the presence of metal ions (Tomita M, et al., *Biochemistry*, 8(12): 5149-60 (1969)). The use of methionine as an antioxidant in formulations appears promising; it has been observed to be effective against a number of oxidative stresses (Lam XM, et al., *J Pharm Sci.*, 86(11): 1250-5 (1997)).

[0087] The amino acids glycine, proline, serine and alanine have been shown to stabilize proteins by the mechanism of preferential exclusion. Glycine is also a commonly used bulking agent in lyophilized formulations (e.g., Neumega®, Genotropin®, Humatropin®). Arginine has been shown to be an effective agent in inhibiting aggregation and has been used in both liquid and lyophilized formulations (e.g., Activase®, Avonex®, Enbrel® liquid). Furthermore, the enhanced efficiency of refolding of certain proteins in the presence of arginine has been attributed to its suppression of the competing aggregation reaction during refolding.

[0088] Antioxidants

[0089] Oxidation of protein residues arises from a number of different sources. Beyond the addition of specific antioxidants, the prevention of oxidative protein damage involves the careful control of a number of factors throughout the manufacturing process and storage of the product such as atmospheric oxygen, temperature, light exposure, and chemical contamination. The most commonly used pharmaceutical antioxidants are reducing agents, oxygen/free-radical scavengers, or chelating agents. Antioxidants in therapeutic protein formulations are water-soluble and remain active throughout the product shelf-life. Reducing agents and oxygen/free-radical scavengers work by ablating active oxygen species in solution. Chelating agents such as EDTA are effective by binding trace metal contaminants that promote free-radical formation. For example, EDTA was utilized in the liquid formulation of acidic fibroblast growth factor to inhibit the metal ion catalyzed oxidation of cysteine residues. EDTA has been used in marketed products like Kineret® and Ontak®.

[0090] In addition to the effectiveness of various excipients to prevent protein oxidation, the potential for the antioxidants themselves to induce other covalent or physical changes to the protein is of concern. For example, reducing agents can cause disruption of intramolecular disulfide linkages, which can lead to disulfide shuffling. In the presence of transition metal ions, ascorbic acid and EDTA have been shown to promote methionine oxidation in a number of proteins and peptides (Akers MJ, and Defelippis MR. Peptides and Proteins as Parenteral Solutions. In: Pharmaceutical Formulation Development of Peptides and Proteins. Sven Frokjær, Lars Hovgaard, editors. Pharmaceutical Science. Taylor and Francis, UK (1999)); Fransson J.R., *J. Pharm. Sci.* 86(9): 4046-1050 (1997); Yin J, et al., *Pharm Res.*, 21(12): 2377-83 (2004)). Sodium thiosulfate has been reported to reduce the levels of light and temperature induced methionine-oxidation in rhuMab HER2; however, the formation of a thiosulfate-protein adduct was also reported in this study (Lam XM, Yang JY, et al., *J Pharm Sci.* 86(11): 1250-5 (1997)). Selection of an appropriate antioxidant is made according to the specific stresses and sensitivities of the protein.

[0091] Metal ions

[0092] In general, transition metal ions are undesired in protein formulations because they can catalyze physical and chemical degradation reactions in proteins. However, specific metal ions are included in formulations when they are co-factors to proteins and in suspension formulations of proteins where they form coordination complexes (e.g., zinc suspension of insulin). Recently, the use of magnesium ions (10 –120 mM) has been proposed to inhibit the isomerization of aspartic acid to isoaspartic acid (WO 2004039337).

[0093] Two examples where metal ions confer stability or increased activity in proteins are human deoxyribonuclease (rhDNase, Pulmozyme®), and Factor VIII. In the case of rhDNase, Ca^{+2} ions (up to 100 mM) increased the stability of the enzyme through a specific binding site (Chen B, et al., *J Pharm Sci.*, 88(4): 477-82 (1999)). In fact, removal of calcium ions from the solution with EGTA caused an increase in deamidation and aggregation. However, this effect was observed only with Ca^{+2} ions; other divalent cations Mg^{+2} , Mn^{+2} and Zn^{-2} were observed to destabilize rhDNase. Similar effects were observed in Factor VIII. Ca^{+2} and Sr^{+2} ions stabilized the protein while others like Mg^{+2} , Mn^{+2} and Zn^{+2} , Cu^{+2} and Fe^{+2} destabilized the enzyme (Fatouros, A., et al., *Int. J. Pharm.*, 155, 121–131 (1997)). In a separate study with Factor VIII, a significant increase in aggregation rate was observed in the presence of Al^{+3} ions (Derrick TS, et al., *J. Pharm. Sci.*, 93(10): 2549-57 (2004)). The authors note that other excipients like buffer salts are often contaminated with Al^{+3} ions and illustrate the need to use excipients of appropriate quality in formulated products.

[0094] Preservatives

[0095] Preservatives are necessary when developing multi-use parenteral formulations that involve more than one extraction from the same container. Their primary function is to inhibit microbial growth and ensure product sterility throughout the shelf-life or term of use of the drug product. Commonly used preservatives include benzyl alcohol, phenol and m-cresol. Although preservatives have a long history of use, the development of protein formulations that includes preservatives can be challenging. Preservatives almost always have a destabilizing effect (aggregation) on proteins, and this has become a major factor in limiting their use in multi-dose protein formulations (Roy S, et al., *J Pharm Sci.*, 94(2): 382-96 (2005)).

[0096] To date, most protein drugs have been formulated for single-use only. However, when multi-dose formulations are possible, they have the added advantage of enabling patient convenience, and increased marketability. A good example is that of human growth hormone (hGH) where the development of preserved formulations has led to commercialization of more convenient, multi-use injection pen presentations. At least four such pen devices containing preserved formulations of hGH are currently available on the market. Norditropin® (liquid, Novo Nordisk), Nutropin AQ® (liquid, Genentech) & Genotropin (lyophilized – dual chamber cartridge, Pharmacia & Upjohn) contain phenol while Somatropin® (Eli Lilly) is formulated with m-cresol.

[0097] Several aspects need to be considered during the formulation development of preserved dosage forms. The effective preservative concentration in the drug product must be optimized. This requires testing a given preservative in the dosage form with concentration ranges that confer anti-microbial effectiveness without compromising protein stability. For example, three preservatives were successfully screened in the development of a liquid formulation for interleukin-1 receptor (Type I), using differential scanning calorimetry (DSC). The preservatives were rank ordered based on their impact on stability at concentrations commonly used in marketed products (Remmele RL Jr., et al., *Pharm Res.*, 15(2): 200-8 (1998)).

[0098] Some preservatives can cause injection site reactions, which is another factor that needs consideration when choosing a preservative. In clinical trials that focused on the evaluation of preservatives and buffers in Norditropin, pain perception was observed to be lower in formulations containing phenol and benzyl alcohol as compared to a formulation containing m-cresol (Kappelgaard A.M., *Horm Res.* 62 Suppl 3:98-103 (2004)). Interestingly, among the commonly used preservative, benzyl alcohol possesses anesthetic properties (Minogue SC, and Sun DA., *Anesth Analg.*, 100(3): 683-6 (2005)).

[0009] Lyophilization

[00100] It is also contemplated that the formulations comprising a VWF polypeptide of the invention may be lyophilized prior to administration. Lyophilization is carried out using techniques common in the art and should be optimized for the composition being developed [Tang et al., Pharm Res. 21:191-200, (2004) and Chang et al., Pharm Res. 13:243-9 (1996)].

[00101] A lyophilization cycle is, in one aspect, composed of three steps: freezing, primary drying, and secondary drying [A.P. Mackenzie, Phil Trans R Soc London, Ser B, Biol 278:167 (1977)]. In the freezing step, the solution is cooled to initiate ice formation. Furthermore, this step induces the crystallization of the bulking agent. The ice sublimes in the primary drying stage, which is conducted by reducing chamber pressure below the vapor pressure of the ice, using a vacuum and introducing heat to promote sublimation. Finally, adsorbed or bound water is removed at the secondary drying stage under reduced chamber pressure and at an elevated shelf temperature. The process produces a material known as a lyophilized cake. Thereafter the cake can be reconstituted with either sterile water or suitable diluent for injection.

[00102] The lyophilization cycle not only determines the final physical state of the excipients but also affects other parameters such as reconstitution time, appearance, stability and final moisture content. The composition structure in the frozen state proceeds through several transitions (e.g., glass transitions, wettings, and crystallizations) that occur at specific temperatures and can be used to understand and optimize the lyophilization process. The glass transition temperature (T_g and/or T_g') can provide information about the physical state of a solute and can be determined by differential scanning calorimetry (DSC). T_g and T_g' are an important parameter that must be taken into account when designing the lyophilization cycle. For example, T_g' is important for primary drying. Furthermore, in the dried state, the glass transition temperature provides information on the storage temperature of the final product.

[00103] Methods of Preparation

[00104] The present invention further contemplates methods for the preparation of pharmaceutical formulations. A variety of aqueous carriers, e.g., sterile water for injection, water with preservatives for multi dose use, or water with appropriate amounts of surfactants (for example, polysorbate-20), 0.4% saline, 0.3% glycine, or aqueous suspensions may contain the active compound in admixture with excipients suitable for the manufacture of aqueous suspensions. In various aspects, such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum

tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyl-eneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate.

[00105] Administration

[00106] To administer compositions to human or test animals, in one aspect, the compositions comprises one or more pharmaceutically acceptable carriers. The phrases "pharmaceutically" or "pharmacologically" acceptable refer to molecular entities and compositions that are stable, inhibit protein degradation such as aggregation and cleavage products, and in addition do not produce allergic, or other adverse reactions when administered using routes well-known in the art, as described below. "Pharmaceutically acceptable carriers" include any and all clinically useful solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like, including those agents disclosed above.

[00107] The pharmaceutical formulations may be administered orally, topically, transdermally, parenterally, by inhalation spray, vaginally, rectally, or by intracranial injection. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intracisternal injection, or infusion techniques. Administration by intravenous, intradermal, intramuscular, intramammary, intraperitoneal, intrathecal, retrobulbar, intrapulmonary injection and or surgical implantation at a particular site is contemplated as well. Generally, compositions are essentially free of pyrogens, as well as other impurities that could be harmful to the recipient.

[00108] Single or multiple administrations of the compositions can be carried out with the dose levels and pattern being selected by the treating physician. For the prevention or treatment of disease, the appropriate dosage will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether drug is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the drug, and the discretion of the attending physician.

[00109] Kits

[00110] As an additional aspect, the invention includes kits which comprise one or more pharmaceutical formulations packaged in a manner which facilitates their use for administration to subjects. In one embodiment, such a kit includes pharmaceutical formulation described herein (e.g., a composition comprising a therapeutic protein or peptide), packaged in a container such as a sealed bottle or vessel, with a label affixed to the container or included in the package that describes use of the compound or composition in practicing the method. In one embodiment, the pharmaceutical formulation is packaged in the container such that the amount of headspace in the container (e.g., the amount of air between the liquid formulation and the top of the container) is very small. Preferably, the amount of headspace is negligible (i.e., almost none). In one embodiment, the kit contains a first container having a therapeutic protein or peptide composition and a second container having a physiologically acceptable reconstitution solution for the composition. In one aspect, the pharmaceutical formulation is packaged in a unit dosage form. The kit may further include a device suitable for administering the pharmaceutical formulation according to a specific route of administration. Preferably, the kit contains a label that describes use of the pharmaceutical formulations.

[00111] Dosages

[00112] The dosage regimen involved in a method for treating a condition described herein will be determined by the attending physician, considering various factors which modify the action of drugs, e.g. the age, condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. By way of example, a typical dose of a recombinant VWF of the present invention is approximately 50 U/kg, equal to 500 µg/kg.

[00113] Formulations of the invention may be administered by an initial bolus followed by a continuous infusion to maintain therapeutic circulating levels of drug product. As another example, the inventive compound may be administered as a one-time dose. Those of ordinary skill in the art will readily optimize effective dosages and administration regimens as determined by good medical practice and the clinical condition of the individual patient. The frequency of dosing will depend on the pharmacokinetic parameters of the agents and the route of administration. The optimal pharmaceutical formulation will be determined by one skilled in the art depending upon the route of administration and desired dosage. See for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA 18042) pages 1435-1712, the disclosure of which is hereby incorporated by reference. Such formulations may influence the physical state, stability, rate of *in vivo* release, and rate of *in vivo* clearance of the administered agents. Depending on the route of administration, a suitable dose may be calculated according to body weight, body surface area or

organ size. Appropriate dosages may be ascertained through use of established assays for determining blood level dosages in conjunction with appropriate dose-response data. The final dosage regimen will be determined by the attending physician, considering various factors which modify the action of drugs, e.g. the drug's specific activity, the severity of the damage and the responsiveness of the patient, the age, condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. As studies are conducted, further information will emerge regarding the appropriate dosage levels and duration of treatment for various diseases and conditions.

[00114] The following examples are not intended to be limiting but only exemplary of specific embodiments of the invention.

Example 1

Shaking experiments

[00115] In order to determine the amount of precipitation of rVWF in various formulations, the percent recovery of rVWF following turbulent shaking was tested under a variety of conditions.

[00116] rVWF in Advate buffer (90 mM NaCl, 1.68 mM CaCl₂, 10 mM L-histidine, 10 mM tris, 0.26 mM glutathione, 23.4 mM trehalose, 175.7 mM mannitol, and 0.1g/L TWEEN-80, pH 7.0) or Advate 1:3 buffer (Advate buffer diluted 3-fold in water) was subjected to turbulent shaking on a shaker at room temperature (RT) for 0 min, 1 min, 2.5 hrs, or 4 days, and percent recovery of the rVWF was measured relative to the starting material prior to shaking. As shown in Table 1, losses of about 40-80% were observed in the Advate buffer while losses of about 20-30% were observed in the Advate 1:3 buffer. VWF antigen VWF:Ag corresponds to the amount of VWF which can be detected in an VWF-specific ELISA using polyclonal anti-VWF antibody, while VWF:RCo corresponds to the amount of VWF which causes agglutination of stabilized platelets in the presence of ristocetin.. In both cases human reference plasma calibrated against the actual WHO standard was used as standard (1 ml of reference plasma usually contains 1U VWF).

[00117] **Table 1. Influence of turbulent shaking time on rVWF recovery**

rVWF	Turbulent shaking at RT	VWF:Ag [U/ml]	Recovery [%]	VWF:RCO [U/ml]	Recovery [%]	RCO/VWF:Ag [U/U]
Advate	0 min	213	100%	104	100%	0.49
	1 min	120	56%			
	2.5 hr	139	65%			
	4 d	37	17%	7	7%	0.19
Advate 1:3	0 min	206	100%	134	100%	0.65
	1 min	152	74%			
	2.5 hr	170	82%			
	4 d	138	67%	131	98%	0.95

[00118] The effect of freeze/thawing and lyophilization was also tested in the shaking experiments. Freezing was performed at -20°C in an -20°C cold room or on dry ice, thawing in both cases at RT and both started from the liquid formulations. As for lyophilization, the formulated VWF samples described herein were frozen within a pilot scale lyophilizer at <=-40°C and were lyophilized using a standard lyo program. Shaking was performed directly with the liquid formulations (2ml in 5 ml vials). As shown in Table 2, percent recovery of rVWF was higher in Advate 1:3 buffer compared to Advate buffer.

[00119] Table 2.

rVWF		VWF:Ag [U/ml]	VWF:Ag recovery [%]	VWF:RCO [U/ml]	VWF:RCO recovery [%]	RCO:Ag [U/U]
Advate	Frozen	213	100%	104	100%	0.49
	Frozen – 3x at -20°C	229	107%	84	81%	0.37
	Frozen – 3x with dry ice	231	108%	72	69%	0.31
	Lyo	242	113%	61	59%	0.25
	Starting material	213	100%	104	100%	0.49
	Heavily shaken for 4 days at RT	37.0	17%	7.2	6.9%	0.19
Advate 1:3	Frozen	206	100%	134	100%	0.65
	Frozen – 3x at -20°C	184	89%	132	99%	0.72
	Frozen – 3x with dry ice	195	94%	128	96%	0.66
	Lyo	195	94%	107	80%	0.55
	Starting material	206	100%	134	100%	0.65
	Heavily shaken for 4 days at RT	138	67%	131	98%	0.95

[00120] Percent recovery was also measured in the shaking experiments with rVWF being stored in syringes with headspace and without headspace. Interestingly, when rVWF is stored in syringes without headspace and shaken as described above, no rVWF precipitation was observed. In contrast, when rVWF is stored in syringes with headspace, some precipitation was observed.

[00121] In summary, turbulent shaking resulted in at least 30% loss of rVWF in Advate buffer or Advate 1:3 buffer, with Advate buffer showing higher loss of recovery compared to Advate 1:3 buffer. Interestingly, the same precipitates observed in the turbulent shaking experiments were not observed when rVWF was stored and transported ~5000 km in an automobile (representing

the expected shaking during transport). Precipitation of rVWF could be eliminated by storage in syringes without headspace.

Example 2

Stability of recombinant VWF

[00122] The stability of rVWF was tested by assessing the activity level of rVWF present in a various formulations.

[00123] As shown in Figure 1, rVWF is not stable in Advate buffer after 26 weeks due to the presence of 0.3 mM glutathione. As shown in Figure 2, however, rVWF is more stable in Advate 1:3 buffer (e.g., for up 12 weeks at 4°C.)

[00124] As shown in Figure 3, the stability of a citrate-based formulation (15 mM sodium citrate, 10 mM CaCl₂, 100 mM NaCl, pH 7.0) is better than Advate 1:3 buffer formulation containing 0.1M glutathione.

[00125] Likewise, the concentration of rVWF was measured over time in various buffers. As shown in Figure 4, Figure 5 and Figure 6, rVWF concentration is stable over time in Advate buffer, Advate 1:3 buffer, and citrate-based buffer, respectively.

Example 4

Characterization of the liquid formulations

[00126] Differential scanning calorimetry (DSC) was used to assess the extent of protein (rVWF) unfolding in various buffers. As shown in Table 3, Advate buffer pH 7.0 is the optimum for stabilization.

[00127] DSC is a thermoanalytical technique in which the difference in the amount of heat required to increase the temperature of a sample and references are measured as a function of temperature. The result of a DSC experiment is a curve of heat flux versus temperature or versus time.

[00128] The Differential Scanning Calorimeter can scan through a range of temperatures while heating and cooling and it determines a phase transition, i.e. melting, crystallization, or glass transition, by measuring the amount of heat needed to reach a set temperature. The calorimeter was calibrated with a set of pure metals (zinc, indium, and tin) that have a known heat capacity, Cp and melting point, Tm. The respective reference buffer was placed into the reference capillary and the rVWF sample was placed into the sample capillary of the

instrument.

[00129] **Table 3. Unfolding temperature in various buffers**

Lot	Buffer	pH	T unfold [°C]
rVWF161A	Advate	7.0	66.0
rVWF161B	Immunate	6.8	64.5
rVWF161C	Citrate	6.8	61.2
rVWF161D	NovoSeven	6.8	64.9
rVWF158	Hepes	7.4	61.3

Buffer components and concentrations:

A) Advate:	5.26g/l NaCl 0.248g/l CaCl ₂ 32g/l D-Mannitol 8g/l Trehalose 1.56g/l L-Histidine 1.2g/l Tris 0.08g/l Glutathione red.	pH=7.0
B) Immunate:	5.25g/l Glycin 2.2g/l NaCl 5.25g/l NaCit3 5.25g/l Lysin-HCl 0.62g/l CaCl ₂	pH=6.8
C) Citrat:	3g/l Glycin 2.92g/l NaCl 2.5g/l NaCit3 30g/l D-Mannitol 10g/l Trehalose	pH=6.8
D) NovoSeven:	0.75g/l Glycin 2.92g/l NaCl 1.47g/l CaCl ₂ 30g/l D-Mannitol	pH=6.8

rVWF158: 20 mM Hepes, 150 mM NaCl, 5g/L sucrose, pH 7.4

[00130] Further, as shown in Figure 7, most formulation excipients increase the unfolding temperature by about 1-2 °C. Figure 8 shows that 10 mM CaCl₂ increases the unfolding

temperature by ~8 °C to ~67 °C, an unfolding temperature which can also be reached by Advate buffer. This effect of CaCl_2 is similar at pH 7.3 and 6.5, as shown in Figure 9. Finally, the effect of trehalose and sucrose were analyzed on the unfolding temperature. Compared to citrate alone, neither trehalose nor sucrose increased the unfolding temperature of rVWF. A summary of the unfolding temperature (T_{max}) data for rVWF in the presence of various excipients is set out in Table 4.

Table 4.

15 mM Sodium Citrate buffer	-	15 mM Tris	15 mM Glycine	50 mM NaCl
ΔH [kJ/mol]	128494.3	656259.7	157352.2	124985.8
Unfolding T [°C] - Peak 1	58.6		59.1	61
Peak 2	65.2	68.5	65.5	
Peak 3	80.4		80.1	81
Peak 4				
15mM Sodium Citrate buffer	15 mM Histidine	20.52 g/L Mannitol	10.26 g/L Trehalose	
ΔH [kJ/mol]	134044.5	1588590.1	612235.9	
Unfolding T [°C] - Peak 1	59.2	58.5	58.5	
Peak 2	65.2	65.5	71.3	
Peak 3	79.3	78.2	81.5	
Peak 4	88.5		92.7	
15mM Sodium Citrate buffer	1 mM CaCl₂	10 mM CaCl₂	32 g/L Saccharose	0.25 mM Saccharose
ΔH [kJ/mol]	266008.2	308171.3	115082.4	246904.6
Unfolding T [°C] - Peak 1	64.5	67.2	59.2	60
Peak 2			66	67
Peak 3	81	83.1	81.1	81.7
Peak 4	91.8	93		
15mM Sodium Citrate buffer	0.1 g/L TWEEN-80	32 g/L Raffinose	Na₂HPO₄/NaH PO₄	7.8 mM Trehalose
ΔH [kJ/mol]	338792.7	127329.2	197967.5	135573.3
Unfolding T [°C] - Peak 1	58.7	60.1	61.4	58.4
Peak 2	64.4	65.8		65.4
Peak 3	81.6	80.3	80.4	80.4
Peak 4			89.2	

[00131] In addition to the various buffers, DSC was used to assess unfolding temperature of rVWF at various pH values in Advate buffer. The results are shown in Table 5, below. Advate buffer pH 7.0 is the optimum for stabilization (i.e., highest unfolding temperature; Peak 1) of rVWF.

[00132] **Table 5.**

pH	Peak 1	Peak 2
5.0	59.5	62.0
6.0	65.2	75.4
7.0	67.2	82.8
8.0	66.6	85.6
9.0	65.0	84.9

[00133] The fluorescence spectrum of rVWF in Advate buffer and Advate 1:3 buffer was assessed after storage at various temperatures for various lengths of time. No (or only slight) change in fluorescence spectrum was observed after storage at 40 °C from 0 to 28 days in either Advate or Advate 1:3 buffers. No difference was observed at other temperatures.

[00134] Likewise, degradation of rVWF was assessed using gelfiltration (Superose 6). While some degradation was observed after 26 weeks at 4 °C in Advate buffer, almost no degradation of rVWF in Advate 1:3 buffer was observed after 26 weeks at 4 °C. At 40 °C, glutathione increased the amount of degradation over time (albeit to a slower extent in Advate 1:3 buffer).

[00135] Based on the above Examples, Advate 1:3 buffer offers an advantage with respect to freeze/thawing and recovery after lyophilization as compared to the undiluted Advate buffer. Moreover, Advate 1:3 buffer can stabilize (e.g., maintain biological activity) rVWF activity during incubation at 40 °C better than Advate buffer. rVWF in Advate 1:3 buffer is stable for 4 weeks of incubation at 4 °C. Finally, DSC has demonstrated that pH 7.0 is optimum for preventing degradation of rVWF (i.e., showed the highest unfolding temperature).

[00136] Thus, in view of the data presented herein, a formulation was proposed for rVWF including 15 mM citrate (or glycine or histidine), 10 mM CaCl₂, pH 6.5-7.3, adjusted to the

desired osmolarity by NaCl. For example, in one embodiment, the citrate-based formula is 15 mM sodium citrate, 10 mM CaCl₂, 100 mM NaCl, pH 7.0.

[00137] Alternatively, an Advate or Advate 1:3 buffer, without glutathione, is also contemplated: Advate: 90mM NaCl, 1.68mM CaCl₂, 10mM L-histidine, 10mM Tris, 0.26mM glutathione, 23.4mM trehalose, 175.7mM mannitol, and 0.1g/L TWEEN-80, pH 7.0; Advate 1:3: 30 mM NaCl, 0.56 mM CaCl₂, 3.3 mM L-histidine, 3.3 mM tris, 7.8 mM trehalose, 58.6 mM mannitol, and 0.03g/L TWEEN-80, ph 7.0.

CLAIMS

1. A stable liquid pharmaceutical formulation of a recombinant von Willebrand Factor (rVWF) comprising: (a) a rVWF; (b) a buffering agent; (c) one or more salts; wherein said rVWF in the pharmaceutical formulation causes agglutination of stabilized platelets in the presence of ristocetin, is stable for at least 26 weeks at 4 °C and comprises a polypeptide that has a molecular weight of approximately 250 kDa selected from the group consisting of:

- a) the amino acid sequence set out in SEQ ID NO: 3;
- b) a biologically active analog or variant of a);
- c) a polypeptide encoded by the polynucleotide set out in SEQ ID NO: 1;
- d) a biologically active analog or variant of c); and
- e) a polypeptide encoded by a polynucleotide that hybridizes to the

polynucleotide set out in SEQ ID NO: 1 under moderately stringent hybridization conditions;

wherein said buffering agent is citrate at a concentration of about 0.1 mM to about 500 mM,

wherein the pH is in a range of about 3.0 to about 9.0; and

wherein said salt is at a concentration of about 0.5 mM to 500 mM.

2. The formulation of claim 1, wherein the rVWF retains at least about 50% agglutination ability of stabilized platelets in the presence of ristocetin at 26 weeks compared to the same material measured at the commencement of storage.

3. The formulation of claim 1, wherein the formulation does not include glutathione.

4. The formulation of any one of claims 1 to 3, wherein the rVWF comprises the amino acid sequence set out in SEQ ID NO: 3.

5. The formulation of any one of claims 1 to 4, wherein the buffering agent is at a concentration orange of about 0.5 mM to 100 mM.

6. The formulation of any one of claims 1 to 5, wherein the buffering agent is at a concentration range of about 1 mM to 50 mM.

7. The formulation of any one of claims 1 to 6, wherein the buffering agent is at a concentration range of about 5 mM to 30 mM
8. The formulation of any one of claims 1 to 7, wherein the buffering agent is at a concentration of 15 mM.
9. The formulation of any one of claims 1 to 3, wherein a first buffering agent and a second buffering agent are each at a concentration of 3.3 mM.
10. The formulation of any one of claims 1 to 9, wherein the salt is at a concentration range of about 0.5 to 300 mM.
11. The formulation of any one of claims 1 to 10, wherein the salt is at a concentration range of about 1 mM to 100 mM.
12. The formulation of any one of claims 1 to 11, wherein the salt is at a concentration range of about 10 mM to 50 mM.
13. The formulation of any one of claims 1 to 12, wherein the salt is at a concentration of 10 mM.
14. The formulation of any one of claims 1 to 13, wherein a first salt is at a concentration of 10 mM and a second salt is at a concentration of 100 mM.
15. A stable liquid pharmaceutical formulation of a recombinant von Willebrand Factor (rVWF) comprising: (a) a rVWF; (b) a buffering agent; and (c) one or more salts,

wherein said rVWF in the pharmaceutical formulation causes agglutination of stabilized platelets in the presence of ristocetin is stable for at least 26 weeks at 4 °C and comprises a polypeptide that has a molecular weight of approximately 250 kDa selected from the group consisting of:

- a) the amino acid sequence set out in SEQ ID NO: 3;
- b) a biologically active analog or variant of a);
- c) a polypeptide encoded by the polynucleotide set out in SEQ ID NO: 1;
- d) a biologically active analog or variant of c); and

e) a polypeptide encoded by a polynucleotide that hybridizes to the polynucleotide set out in SEQ ID NO: 1 under moderately stringent hybridization conditions;

wherein the buffering agent is citrate at a concentration of about 15 mM, wherein the pH is in a range of about 3.0 to about 9.0; and

wherein a first salt is sodium chloride at a concentration of about 100 mM and a second salt is calcium chloride at a concentration of about 10 mM.

16. The formulation of any one of the preceding claims, wherein the buffering agent is sodium citrate.

17. The formulation of any one of the preceding claims, wherein the pH is in the range of 5.5 to 8.5.

18. The formulation of any one of the preceding claims, wherein the pH is in the range of 6.0 to 8.0.

19. The formulation of any one of the preceding claims, wherein the pH is in the range of 6.5 to 7.5.

20. The formulation of any one of the preceding claims, wherein the pH is 7.0.

21. The formulation of claim 19, wherein a first salt is at a concentration of 30 mM and a second salt is at a concentration of 0.56 mM.

22. A stable liquid pharmaceutical formulation as defined in claim 1 or claim 15 and as substantially described herein with reference to one or more of the accompanying examples.

FIG. 1




FIG. 2




FIG. 3




FIG. 4






FIG. 5




6 / 9

FIG. 6




7 / 9

FIG. 7



8 / 9

FIG. 8



9 / 9

FIG. 9

